Ovid Therapeutics

Ovid Therapeutics' Pipeline

Ovid Therapeutics has a robust pipeline dedicated to developing innovative treatments for epilepsies and other brain conditions. Leading the charge is Soticlestat, a cholesterol 24-hydroxylase inhibitor, currently in Phase 3 trials for Dravet syndrome and Lennox-Gastaut syndrome. The company's portfolio also includes OV888, a selective ROCK2 inhibitor developed with Graviton Biosciences; OV329, a next-generation GABA-aminotransferase inhibitor in Phase 1 trials; and OV350, a KCC2 transporter activator optimized for both intravenous and oral formulations to treat resistant epilepsies and neuropathologies. These diverse projects underscore Ovid's commitment to improving patient outcomes through cutting-edge science.

Ovid Therapeutics' Collaborations

Ovid Therapeutics has forged key collaborations to further its mission of developing breakthrough therapies. The company works closely with Graviton Biosciences on OV888 and has strategic partnerships with industry giants AstraZeneca and Takeda. Additionally, Ovid collaborates with the Columbia University Irving Medical Center to explore genetic-based therapies. These partnerships enhance Ovid's research capabilities, allowing the company to leverage external expertise and accelerate the development of its innovative therapies.

Ovid Therapeutics' History

Founded in April 2014, Ovid Therapeutics has quickly become a leader in the development of small molecule therapies for neurological conditions. Headquartered at Hudson Commons, New York, and with lab space at Tufts Launchpad BioLabs in Boston, the company's early success includes the development and subsequent sale of its late-stage clinical asset, Soticlestat, to Takeda. Soticlestat is now in Phase 3 trials, signaling Ovid's capability to advance promising treatments from conception to late-stage development. This history of rapid progress and strategic growth positions Ovid as a significant player in the pharmaceutical industry.

Ovid Therapeutics' Commitment to Patient Advocacy

Ovid Therapeutics places a strong emphasis on patient advocacy, actively engaging with various patient advocacy groups. This commitment ensures that the company remains attuned to the needs and challenges faced by those living with epilepsies and brain conditions. By fostering these relationships, Ovid not only supports the communities it serves but also gains valuable insights that inform its research and development efforts. This patient-centric approach underscores Ovid's dedication to improving the lives of individuals impacted by neurological disorders.

Ovid Therapeutics' Workplace Culture

Ovid Therapeutics prides itself on maintaining a diverse and inclusive workplace culture. The company offers a comprehensive range of benefits to its employees, including health and wellness programs, financial well-being support, and initiatives to promote work-life balance. This supportive environment fosters innovation and collaboration, enabling employees to thrive both personally and professionally. By prioritizing diversity and inclusion, Ovid ensures that a variety of perspectives contribute to its mission of developing transformative therapies for neurological conditions.